JAMA Editors' Summary Personalized Antidepressant Decision-Support, Insufficient Sleep in Adolescents, Rural Health Funding, and more
9 snips
Mar 6, 2026 A trial testing personalized antidepressant selection and its impact on early treatment persistence. Rising rates of insufficient and very-short sleep among U.S. high school students. State-level mismatches between rural health funding, mortality, and population. Discussion of how physicians' roles may shift as artificial intelligence becomes more prominent.
AI Snips
Chapters
Transcript
Episode notes
PETRUSHKA Cut Early Antidepressant Dropout
- A web-based tool named PETRUSHKA reduced 8-week antidepressant discontinuation from 27% to 17% versus usual care.
- The tool combines clinical/demographic predictors with patient preferences to personalize antidepressant selection across >500 adults with major depressive disorder.
Patient Preference Improves Antidepressant Outcomes
- Patient preference can offer meaningful clinical benefit without waiting for biological markers like genomics or proteomics.
- Dr. Simon emphasized preference-based selection as low-risk, low-cost, and not delaying treatment implementation.
Adolescent Insufficient Sleep Rose Substantially
- Insufficient sleep (≤7 hours) among U.S. high school students rose from ~69% in 2007 to ~77% in 2023 in a sample >120,000.
- Very short sleep (≤5 hours) increased from ~16% to ~23%, driving the overall trend across nearly all subgroups.